The IRB Barcelona spin-off Gate2Brain has won the Senén Vilaró Prize for pioneering technology facilitating drug delivery to the brain. Established in 2020 with support from Botín Foundation's Mind the Gap Programme and BStartup Health, it received a €2.5M EIC Accelerator grant last year. Leveraging peptides developed over 15 years in IRB Barcelona’s former Peptide and Protein laboratory, Gate2Brain aims to enhance brain disease treatment efficacy. Led by CEO Dr. Meritxell Teixidó, the company's innovative approach utilises shuttle peptides to cross the blood-brain barrier and deliver therapeutic molecules, initially targeting pediatric brain tumours.
Gate2Brain's groundbreaking technology holds promise for oncology, rare diseases, and pediatrics, with patents exclusively licensed to the company. Positioned in the rapidly growing drug transport sector for the central nervous system, Gate2Brain's business model focuses on licensing agreements with pharmaceutical companies. Recognised by the Senén Vilaró Prize jury for its achievements, Gate2Brain is set for a promising future in revolutionising brain disease treatments.
For more information: https://www.irbbarcelona.org/en/news/innovation/irb-barcelona-spin-gate2brain-wins-senen-vilaro-prize-development-technology
